At NeXell, we are equipping immune cells with built-in intelligence and multi-level auto-switches to enable self-regulation and dynamic adjustment in response to the diverse and evolving nature of cancers.
Cell therapies have been life-saving for patients with blood cancers—especially those left with no other treatment options. But despite that success, they've shown very limited efficacy in solid tumors and come with major challenges like toxicity and short durability.
We're developing new generations of CARs and smart cell therapies with built-in intelligence and multi-level auto-switches to enhance safety, efficacy and durability of cell therapies and expand their application to other type of cancers (solid tumors) beside blood malignancies.
Our platform is uniquely positioned to seamlessly integrate into existing CAR-T programs, enhancing efficacy, safety, and durability, while also enabling the development of standalone therapeutic products within our internal pipeline.
Our smart cell therapies aim to reduce side effects and improve treatment outcomes, allowing patients to maintain better quality of life during and after treatment.
In the U.S. alone, over two million patients are diagnosed annually. We're working to bring hope to these patients by developing more effective therapies for a wider range of cancers.
While CAR-T therapies have shown remarkable success in blood cancers, solid tumors—accounting for more than 90% of all cancer cases—remain largely untapped.
Unlike many competitors focused solely on blood cancers, our technology extends to solid tumors, which represent 90% of cancer cases.
Our platform is drug-free and agnostic to cancer type, CAR type, and cell type, providing versatility across multiple applications.
We integrate built-in controls and multi-level auto-switches, spanning from gene transcription to protein translation, enhancing safety and efficacy.
Learn more about our technology or explore partnership opportunities.